Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 26th Preview)
-
Regulatory approvals and rejections in MS
Europe moved to greenlight Sanofi’s MS therapy Cenrifki (tolebrutinib) after U.S. regulators previously rejected it. Sanofi received a positive CHMP opinion for Cenrifki for non-relapsing secondary progressive multiple sclerosis. The review follows a December FDA complete response letter for the same drug, which cited concerns that prevented approval in the U.S. The European recommendation is based on the 1,131-patient Phase III HERCULES study, supported by GEMINI 1 and GEMINI 2 data from relapsing MS. CHMP said the benefits included a 31% reduction in risk of six-month confirmed disability progression and a 38% reduction in adjusted mean new or enlarging T2-hyperintense lesions versus placebo. Separately, an EMA endorsement for Cenrifki also signals how regulators are weighing evidence in progressive, non-relapsing MS subpopulations—an outcome that could reshape Sanofi’s commercial timeline across the EU.
-
FDA compliance and manufacturing setbacks
Grace Therapeutics’ lead aneurysmal subarachnoid hemorrhage program hit a regulatory roadblock as the FDA issued a complete response letter for GTx-104. The CRL cited manufacturing and nonclinical deficiencies rather than problems with efficacy or safety. Specifically, the FDA pointed to leachables for product packaging, nonclinical product toxicology risk assessments, and product manufacturing deficiencies at the company’s contract manufacturing organization. Grace said it will request a Type A meeting with the FDA to clarify the path forward and determine next steps. The company’s setback delays hopes of updating the standard of care in the condition after a positive trial signal. For investors and development teams, the decision underscores how CMC and toxicology packages can become gating items even when clinical data are supportive.
-
Neuro oncology and immune-cell engineering
Researchers reported a strategy to genetically program neutrophils in vivo for glioma treatment, targeting a longstanding limitation in cell-based engineering. The work describes direct genetic modification of neutrophils—cells that are abundant in circulation and act within the tumor microenvironment—while addressing prior difficulty in programming them for therapeutic use. In a preclinical framing, the approach aims to turn neutrophils into an effective in situ delivery platform for glioma, potentially broadening the cellular immunotherapy toolbox beyond more commonly engineered lymphocytes. The announcement adds to the momentum in engineered innate-cell therapies for solid tumors, where tumor trafficking and durable activity have remained key development hurdles.
-
Epigenetic vulnerability in cancer
New cancer biology findings pinpoint KMT2C/D loss as a targetable weakness by linking the alteration to downstream dependencies in tumor growth. The study frames KMT2C/D as part of broader epigenetic regulation through the COMPASS complex (Complex of Proteins Associated with Set1), which controls differentiation and cell identity programs. By mapping how loss of these epigenetic regulators reshapes the tumor state, the researchers argue it creates exploitable vulnerabilities—an angle that may support future combination strategies, especially in settings where current targeted therapies struggle. For translational teams, the key development is a mechanistic rationale that can inform biomarker selection and therapeutic target prioritization.
-
AI-driven drug discovery for neurodegeneration
DeepDrugDiscovery unveiled an AI screening platform designed to discover blood–brain barrier–permeable autophagy enhancers for Alzheimer’s disease. The platform focuses on a core translational problem: enhancing autophagy in the brain without triggering systemic side effects. DeepDrugDiscovery combines AI-driven screening with a BBB permeability goal, aiming to identify candidates that can modulate disease-relevant pathways in the CNS. The announcement positions the tool as a mechanism-first discovery approach for neurodegenerative programs, where drug exposure in brain tissue is often the bottleneck. If validated in subsequent preclinical and clinical work, the pipeline could expand autophagy-targeting strategies with better CNS delivery and reduced off-target risk.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.